Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2876753 | 0.79 | ALDH1A1 (0.43) | CA1CA2CA12CA7CA9 | |
| SCHEMBL18029867 | 0.74 | CA12 (0.39) | CA1CA2CA12CA7CA9 | |
| SCHEMBL531291 | 0.74 | SMN1; SMN2 (0.47) | MAPTALDH1A1CYP3A4 | |
| SCHEMBL18844566 | 0.73 | PTPN1 (0.39) | CA1CA2CA12CA7CA9 | |
| SCHEMBL24709121 | 0.70 | NOS3 (0.43) | CA1CA2CA12CA7CA9 | |
| SCHEMBL2965027 | 0.70 | ALDH1A1 (0.42) | CA1CA2CA12CA7CA9 | |
| SCHEMBL2096172 | 0.69 | ALDH1A1 (0.50) | CA1CA2CA12CA7CA9 | |
| SCHEMBL2337842 | 0.68 | CYP1A2 (0.55) | MAPTPTPN1CYP1A2ALDH1A1CYP3A4 | |
| SCHEMBL25316972 | 0.67 | IDO1 (0.46) | MAPTALDH1A1CYP3A4 | |
| SCHEMBL24709120 | 0.66 | PTPN1 (0.39) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228777-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2025-07-17 | — | — | US | disclosed |
| US-12263248-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20220409536-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2022-12-29 | — | — | US | disclosed |
| US-20220409536-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2022-12-29 | — | — | US | disclosed |
| EP-3853202-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ModernaTX, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| WO-2020061367-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| WO-2020061367-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12263248-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | LNPK, PLTP, PLIN3 | CA1 4349/4885CA2 4394/4885CA12 4124/4885 |
| US-20220409536-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | CA1 4349/4885CA2 4394/4885CA12 4124/4885 |
| US-20250228777-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | CA1 4349/4885CA2 4394/4885CA12 4124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.